peptamen neutrální - Keresési eredmények

Európai Unió - spanyol - EMA (European Medicines Agency)

zoledronic acid teva pharma

teva b.v. - ácido zoledrónico - osteoporosis; osteitis deformans; osteoporosis, postmenopausal - medicamentos para el tratamiento de enfermedades óseas - treatment of osteoporosis: , in post-menopausal women;, in men; , at increased risk of fracture including those with a recent low-trauma hip fracture. treatment of osteoporosis associated with long-term systemic glucocorticoid therapy: , in post-menopausal women;, in men; , at increased risk of fracture. el tratamiento de la enfermedad de paget de los huesos en adultos.

Európai Unió - spanyol - EMA (European Medicines Agency)

ubac

laboratorios hipra, s.a. - el ácido lipoteicoico de la biopelícula de la adhesión de los componentes de streptococcus uberis, cepa 5616 - inmunológicos para bovidae - ganado - para la inmunización activa de las vacas sanas y novillas para reducir la incidencia de la clínica de las infecciones intramamarias causada por streptococcus uberis, para reducir el recuento de células somáticas en streptococcus uberis positivo trimestre de muestras de leche y reducir la producción de leche de las pérdidas causadas por streptococcus uberis las infecciones intramamarias.

Európai Unió - spanyol - EMA (European Medicines Agency)

exparel liposomal

pacira ireland limited - bupivacaine - acute pain - amides, anesthetics, local - exparel liposomal is indicated:in adults as a brachial plexus block or femoral nerve block for treatment of post-operative pain. in adults and children aged 6 years or older as a field block for treatment of somatic post-operative pain from small- to medium-sized surgical wounds.

Európai Unió - spanyol - EMA (European Medicines Agency)

mhyosphere pcv id

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - cerdos - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

Európai Unió - spanyol - EMA (European Medicines Agency)

skytrofa (previously lonapegsomatropin ascendis pharma)

ascendis pharma endocrinology division a/s - lonapegsomatropin - growth and development - hormonas hipofisarias e hipotalámicas y análogos - growth failure in children and adolescents aged from 3 years up to 18 years due to insufficient endogenous growth hormone secretion (growth hormone deficiency [ghd]),.